Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Relieves pain associated with post-herpetic neuralgia. ANDA 209190, held by Ibsa. Lidocaine.
As of Nov 15, 2026, ANDA 209190 (Lidocaine), held by Ibsa, was first approved by FDA on Apr 30, 2020, with 0 approved supplements and 0 published complete response letters.
First approved: Apr 30, 2020
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
INDICATION AND USAGE Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
